Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation

PURPOSE AND DESIGN: Mechanism(s) by which the multi-kinase inhibitor sorafenib and the histone deacetylase inhibitor vorinostat interact to kill hepatic, renal and pancreatic adenocarcinoma cells have been defined. RESULTS: Low doses of sorafenib and vorinostat interacted in vitro in a synergistic f...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Zhang, Guo, Park, Margaret A., Mitchell, Clint, Hamed, Hossein, Rahmani, Mohammed, Martin, Aditi Pandya, Curiel, David T., Yacoub, Adly, Graf, Martin, Lee, Ray, Roberts, John D., Fisher, Paul B., Grant, Steven, Dent, Paul
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2008
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2561272/
https://ncbi.nlm.nih.gov/pubmed/18765530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0469
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia